Vaxart Advances Second-Generation Norovirus Oral Vaccine with Improved Immune Response Data
核心洞察
Vaxart will present Phase 1 clinical trial results for its second-generation norovirus (搜索) oral pill vaccine (搜索) at IDWeek 2025, demonstrating improved immune responses to GI.1 and GII.4 strains.
The company's proprietary oral vaccine platform eliminates refrigeration requirements and needle-stick injury risks while generating both systemic and mucosal immune responses.
Vaxart's development pipeline includes oral pill vaccines for coronavirus (搜索), norovirus (搜索), influenza (搜索), and a therapeutic HPV (搜索) vaccine for immune-oncology applications.
Vaxart, Inc. will present Phase 1 clinical trial data for its second-generation norovirus (搜索) oral pill vaccine (搜索) candidate at IDWeek 2025, showcasing improved immune responses against key norovirus strains. The clinical-stage biotechnology company announced that research on its bivalent vaccine candidate will be featured in the "Late Breaking Trial Results For Viral and Bacterial Infections" session on October 20, 2025.
Enhanced Immune Response Profile
The open-label Phase 1 clinical trial demonstrated improved immune responses to norovirus (搜索) strains GI.1 and GII.4 from the next-generation oral bivalent vaccine candidate. Dr. Nicholas J. Bennett, Vaxart's Medical Director, will present the findings during the IDWeek conference taking place at the Georgia World Congress Center in Atlanta from October 19-22, 2025.
The presentation, titled "An Open-Label Phase 1 Clinical Trial Demonstrating Improved Immune Responses to Norovirus (搜索) Strains GI.1 and GII.4 from a Next Generation Oral Bivalent Vaccine Candidate," will be delivered on Monday, October 20, 2025, from 1:45 PM to 3:00 PM ET in location B401-B402.
Proprietary Oral Vaccine Platform
Vaxart's vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. The company's proprietary pill vaccine delivery platform has demonstrated both systemic and mucosal immune responses with a favorable safety and tolerability profile in clinical trials.
Dr. Sean Tucker, Founder and Chief Scientific Officer, will also present research on the oral bivalent vaccine for norovirus (搜索) protection at the World Vaccine Congress Europe 2025 in Amsterdam. His presentation, scheduled for October 15 at 11:45 a.m. CEST, will focus on "recent improvements to improve immunogenicity and potentially efficacy."
Comprehensive Development Pipeline
Vaxart's development programs currently include pill vaccines designed to protect against coronavirus (搜索), norovirus (搜索) and influenza (搜索), as well as a therapeutic vaccine for human papillomavirus (搜索) (HPV (搜索)), which represents the company's first immune-oncology indication. The company believes its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning it to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications.
The company has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus (搜索) and TLR3 (搜索) agonists. Vaxart's mission focuses on improving global public health by developing a transformative oral pill vaccine (搜索) platform to solve serious health challenges facing society.